Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En første-i-menneskelig studie av KK2223 hos deltakere med tilbakefall eller ildfast T-celle ikke-Hodgkin lymfom

29. september 2026 oppdatert av: Kyowa Kirin, Inc.

En fase 1, multisenter, åpen etikett, ikke-randomisert, dose-opptrapping og utfyllingsstudie av KK2223 hos deltakere med tilbakefall eller ildfast T-celle non Hodgkin lymfom

The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)

Studietype

Intervensjonell

Registrering (Antatt)

72

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Duarte, California, Forente stater, 91010
        • Har ikke rekruttert ennå
        • City of Hope
        • Hovedetterforsker:
          • Christina Poh
        • Ta kontakt med:
          • Christina Poh
          • Telefonnummer: 916-734-7131
          • E-post: cpoh@coh.org
      • Orange, California, Forente stater, 92868
        • Har ikke rekruttert ennå
        • University of California, Irvine Medical Center - Hematology/Oncology
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lauren Pinter Brown
      • Stanford, California, Forente stater, 94305
        • Rekruttering
        • Stanford University School of Medicine
        • Hovedetterforsker:
          • Youn Kim
        • Ta kontakt med:
    • Florida
      • Tampa, Florida, Forente stater, 33612
        • Har ikke rekruttert ennå
        • Moffit Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yumeng Zhang
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Har ikke rekruttert ennå
        • Emory University Medical Center
        • Hovedetterforsker:
          • Pamela Allen
        • Ta kontakt med:
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • Har ikke rekruttert ennå
        • University of Iowa Health
        • Hovedetterforsker:
          • Eric Mou
        • Ta kontakt med:
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Har ikke rekruttert ennå
        • Beth Israel Deaconess Medical Center - Research
        • Ta kontakt med:
        • Hovedetterforsker:
          • Salvia Jain
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University School of Medicine - Oncology Hospital - Public
        • Hovedetterforsker:
          • Neha Mehta Shah
        • Ta kontakt med:
    • New Jersey
      • Hackensack, New Jersey, Forente stater, 07601-2105
        • Har ikke rekruttert ennå
        • Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
        • Hovedetterforsker:
          • Tatyana Feldman
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10021-6007
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
        • Hovedetterforsker:
          • Jasmine Zain
        • Ta kontakt med:
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • Har ikke rekruttert ennå
        • University Hospitals Cleveland Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kevin Cooper
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Har ikke rekruttert ennå
        • Oregon Health & Science University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Craig Okada
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Har ikke rekruttert ennå
        • University of Pennsylvania - Abramson Cancer Center
        • Hovedetterforsker:
          • Stefan Barta
        • Ta kontakt med:
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • The University of Texas - MD Anderson Cancer Center
        • Hovedetterforsker:
          • Ranjit Nair
        • Ta kontakt med:
      • Bergamo, Italia, 24127
        • Har ikke rekruttert ennå
        • Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
        • Hovedetterforsker:
          • Giuseppe Gritti
        • Ta kontakt med:
      • Bologna, Italia, 40138
        • Har ikke rekruttert ennå
        • Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
        • Ta kontakt med:
        • Hovedetterforsker:
          • Luigi Zinzani Pier
      • Torino, Italia, 10126
        • Har ikke rekruttert ennå
        • AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
        • Ta kontakt med:
        • Hovedetterforsker:
          • Federica Cavallo
    • Torino
      • Candiolo, Torino, Italia, 10060
        • Har ikke rekruttert ennå
        • Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
        • Hovedetterforsker:
          • Umberto Vitolo
        • Ta kontakt med:
      • Madrid, Spania, 28027
        • Har ikke rekruttert ennå
        • Clinica Universidad de Navarra - Hematología y Hemoterapia
        • Ta kontakt med:
        • Hovedetterforsker:
          • Migue Canales Albendea
    • Barcelona
      • Badalona, Barcelona, Spania, 8036
        • Har ikke rekruttert ennå
        • Hospital Clinic De Barcelona - Hematología
        • Hovedetterforsker:
          • Pablo Mozas
        • Ta kontakt med:
      • L'Hospitalet de Llobregat, Barcelona, Spania, 8907
        • Har ikke rekruttert ennå
        • Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
        • Hovedetterforsker:
          • Eva Domingo Domenech
        • Ta kontakt med:
    • Navarre
      • Pamplona, Navarre, Spania, 31008
        • Har ikke rekruttert ennå
        • Clinica Universidad de Navarra - Hematología
        • Ta kontakt med:
        • Hovedetterforsker:
          • Miguel Canales Albendea

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
  • PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
  • Availability of tumor tissue (current or archival) is required.
  • Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
  • ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
  • Body weight 40 kg to ≤ 200 kg
  • Life expectancy ≥3 months.
  • Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
  • Restrictions on gamete donation and freezing during and after treatment.
  • Ability to provide informed consent and comply with study procedures. -

Exclusion Criteria:

  • Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
  • Pregnant or breastfeeding females, or those intending pregnancy.
  • History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
  • Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
  • Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
  • Use of other investigational drugs within 14 days or 5 half-lives before treatment.
  • Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
  • Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
  • Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
  • Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
  • Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
  • Prolonged QT/QTc interval (e.g., QTcF >480 ms).
  • Active second primary malignancies except specified non-exclusionary cases.
  • CNS involvement.
  • Any condition that may impair compliance or study completion as judged by the Investigator.
  • Known hypersensitivity to any excipients in the drug formulation.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part One (Dose Escalation)

In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design.

Intravenous infusion

Eksperimentell: Part Two (Backfill)

Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment.

Intravenous infusion

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Vital signs (mmHg in Systolic/Diastolic blood pressure)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Pulse rate (beats/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Respiratory Rate (breath/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Temperature (°Celcius)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

ECG parameters (PR interval, QRS interval, QT interval, QTc interval)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD)

Through study completion, an average of 1.5 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mean Blood Drug Concentration
Tidsramme: Through study completion, an average of 1.5 years

The mean drug concentration in the blood

Through study completion, an average of 1.5 years
To evaluate the immunogenicity of KK2223.
Tidsramme: Through study completion, an average of 1.5 years

Incidence of Anti drug antibodies (ADA) in blood

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years

% in Overall Response Rate (ORR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years

% in Compartment Response (if applicable)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years

Time unit (week/month) in Duration of Response (DOR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Response (TTR)

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
Tidsramme: Through study completion, an average of 1.5 years

The maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
Tidsramme: Through study completion, an average of 1.5 years

A measure of the overall drug exposure over time

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Tidsramme: Through study completion, an average of 1.5 years

The time taken to reach the maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
Tidsramme: Through study completion, an average of 1.5 years

The time required for the drug concentration to decrease by 50%

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Clearance (CL)
Tidsramme: Through study completion, an average of 1.5 years

Rate of drug elimination from the body

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
Tidsramme: Through study completion, an average of 1.5 years

Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues

Through study completion, an average of 1.5 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. september 2026

Primær fullføring (Antatt)

1. mars 2029

Studiet fullført (Antatt)

1. september 2030

Datoer for studieregistrering

Først innsendt

12. august 2025

Først innsendt som oppfylte QC-kriteriene

17. september 2025

Først lagt ut (Faktiske)

25. september 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere